(UroToday.com) The 2023 ESMO annual meeting included a session on prostate cancer, featuring a presentation by Dr. Daniel Petrylak discussing radiographic progression-free survival (rPFS) in patients ...
BERLIN -- The investigational tyrosine kinase inhibitor (TKI) zanzalintinib plus atezolizumab (Tecentriq) significantly improved overall survival (OS) among previously treated patients with metastatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results